Management of myeloproliferative neoplasms: From academic guidelines to clinical practice

Current Hematologic Malignancy Reports

Volumn 7, Issue 1, 2012, Pages 50-56

  Barosi, Giovanni ^a   Lupo, Letizia ^a   Rosti, Vittorio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Epigenetic drugs; Essential thrombocythemia; Everolimus; JAK inhibitors; JAK2 V617F; Lenalidomide; Myelofibrosis; Myeloproliferative neoplasms; Polycythemia vera; Pomalidomide; Stem cell; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ANDROGEN; ANTINEOPLASTIC AGENT; CORTICOSTEROID; EVEROLIMUS; HYDROXYUREA; IMMUNOMODULATING AGENT; JANUS KINASE 2; JANUS KINASE INHIBITOR; LENALIDOMIDE; PEGINTERFERON; POMALIDOMIDE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; RUXOLITINIB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; CLINICAL PRACTICE; GENE MUTATION; HUMAN; LOW DRUG DOSE; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; PHILADELPHIA 1 CHROMOSOME; POLYCYTHEMIA VERA; PRACTICE GUIDELINE; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOSIS; THROMBOSIS PREVENTION; DRUG ANTAGONISM; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MYELOPROLIFERATIVE DISORDER; REVIEW; RISK ASSESSMENT; VEIN THROMBOSIS;

ANEMIA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JANUS KINASE 2; MOLECULAR TARGETED THERAPY; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PRACTICE GUIDELINES AS TOPIC; PROTEIN KINASE INHIBITORS; PYRAZOLES; RISK ASSESSMENT; THROMBOCYTHEMIA, ESSENTIAL; VENOUS THROMBOSIS;

EID: 84859255284     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0109-7     Document Type: Article

References (55)

1. Swerdlow SH, Campo E, Harris NL, et al (Eds): WHO Classification of Tumours of Haemopoietic and Lymphoid Tissues. IARC: Lyon 2008.
2. Mesa RA, Green A, Barosi G, et al. MPN-associated myelofibrosis (MPN-MF). Leuk Res. 2010;35:12-3.
3. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemiavera. Nature. 2005;434:1144-8. (Pubitemid 40663494)
4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet.2005;365: 1054-61. (Pubitemid 40386783)
5. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med.2005;352:1779-90. (Pubitemid 40570926)
6. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-97. (Pubitemid 40544655)
7. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms.Blood. 2011;118:1723-35.
8. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of lowdose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-24. (Pubitemid 38056222)
9. Barbui T, Thiele J, Passamonti F, et al.: Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011;29:3179-3184. This paper provides evidence that distinguishing true ET from prefibrotic myelofibrosis is relevantfor the prognosis of the patients.
10. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl JMed. 2005;353:33-45. (Pubitemid 41007805)
11. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007;92:135-6. (Pubitemid 46232672)
12. Girodon F, Dutrillaux F, Broséus J, et al. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: A population-based study of 311 patients. Leukemia. 2010;24:900-3.
13. Chim CS, Kwong YL, Lie AK, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch InternMed. 2005;165:2651-8. (Pubitemid 41785064)
14. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) alleleburden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24:1574-9.
15. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109:2310-3. (Pubitemid 46425868)
16. Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol. 2008;26:2732-6.
17. Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. A metaanalysisof studies reporting the relationship between JAK2 V617F mutational status and the risk of thrombosis in essential thrombocythemia.Haematologica. 2008;93:1412-4.
18. Dahabreh IJ, Zoi K, Giannouli S, Zoi C, et al. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2009;33:67-73.
19. Barbui T, Barosi G, Birgegard G, et al.: Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and managementrecommendations from European LeukemiaNet. J Clin Oncol 2011;29:761-770. These are the most updated recommendations for the management of MPNs.
20. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21:270-6. (Pubitemid 46158119)
21. Harrison CN, Bareford D, Butt N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010;149:352-75.
22. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113:2895-901.
23. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304:441-7. (Pubitemid 11178999)
24. European Organization for Research on Treatment of Cancer. Treatment of polycythemia vera by radiophosphorus or busulphan: a randomized trial. Br J Cancer. 1981;44:75-80.
25. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29:3907-13.
26. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065-72.
27. Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556-62. (Pubitemid 20087557)
28. Ruggeri M, Finazzi G, Tosetto A, et al. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol.1998;103:772- 7. (Pubitemid 28545314)
29. Randi ML, Rossi C, Fabris F, Girolami A. Essential thrombocythemia in young adults: major thrombotic complications and complicationsduring pregnancy-a follow-up study in 68 patients. Clin Appl Thromb Hemost. 2000;6:31-5. (Pubitemid 30022952)
30. Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116:1205-10.
31. Squizzato A, Romualdi E, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev. 2008;16(2):CD006503.
32. van Genderen PJ, Michiels JJ. Erythromelalgic, thrombotic and hemorrhagic manifestations of thrombocythemia. Presse Med.1994;23:73-7. (Pubitemid 24055523)
33. Verstovsek S, Passamonti F, Rambaldi A, et al. Durable Responses with the JAK1/JAK2 Inhibitor, INCB018424, in Patients with PolycythemiaVera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU). Blood. 2010;116:142. abstract 313.
34. Tefferi A. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:292-301.
35. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108:1158-64. (Pubitemid 44232010)
36. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009;27:4760-6.
37. Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase-2 trial E4903. Blood. 2010;116:4436-8.
38. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108:1497-503. (Pubitemid 44316114)
39. Jabbour E, Thomas D, Kantarjian H, et al. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 2011;118:899-902.
40. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J ClinOncol. 2009;27:4563-9.
41. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of lowdosepomalidomide in myelofibrosis. Leukemia. 2011;25:301-4.
42. Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol. 2010;85:129-30.
43. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93:2831-8. (Pubitemid 29200773)
44. Zang DY, Deeg HJ. Allogeneic hematopoietic cell transplantation for patients with myelofibrosis. Curr Opin Hematol. 2009;16:140-6.
45. Kerbauy DMB, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis,advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13:355-65.
46. Rondelli D, Barosi G, Bacigalupo A, et al. Myeloproliferativediseases- research consortium. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediateor high-risk patients with myelofibrosis with myeloid metaplasia. Blood. 2005;105:4115-9. (Pubitemid 40656163)
47. Kröger N, Holler E, Kobbe G, et al.: Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009;114:5264-5270. The most extensive study on stem cell transplantation in myelofibrosis.
48. Deeg HJ, Appelbaum FR. Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis. Blood. 2011;117:7185.
49. Bacigalupo A, Soraru M, Dominietto A, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant. 2010;45:458-63.
50. Mesa RA, Verstovsek S, Rivera C, et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia. 2009;23:180-2.
51. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150:446-55.
52. Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 studyin patients with myelofibrosis. Blood. 2011;118:2069-76.
53. Verstovsek S, Kantarjian H, Mesa RA, et al.: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-1127. This article reports on a clinical study of the use of a JAK inhibitor in MPN-associated myelofibrosis.
54. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010;115:1131-6.
55. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29:789-96.